The News
Large-scale trials of three vaccines against the deadly Bundibugyo Ebola strain in the epicenter of DR Congo’s outbreak could yield a breakthrough early next year if security challenges can be overcome, the head of a global vaccine body told Semafor.
The Bundibugyo strain, for which there is no proven vaccine, has killed more than 5,500 people since May’s declaration of an outbreak — now the second-largest ever recorded. Most of the cases, amounting to more than 11,000, have been concentrated in the conflict-hit east of the country.
The Tumaini trial — a study to test vaccine candidates — will see jabs tested on at least 1,000 people to check their safety and efficacy. A trial of Ervebo, a vaccine developed by Merck that has been approved for use against the more common Zaire strain of Ebola, began on Oct. 23. The two other vaccines, which were designed to target the Bundibugyo strain and will join the trial in the next few days, are a jab developed by Oxford University scientists and another by Moderna that harnesses technology used to create vaccines for COVID-19.
“In a best case, we could look towards early next year for a result,” said Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations.




